• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
OPL
Click for more information
0.00% 1.8¢

OPYL LIMITED - Corporate Spotlight

Market Cap $3.072M  ! watchlist Created with Sketch. Add to my watchlist
Technology Software - Application

Opyl Limited is an Australia-based artificial intelligence (AI) company. The Company... Opyl Limited is an Australia-based artificial intelligence (AI) company. The Company leverages data and technology to transform the landscape of clinical trials and medical research. It is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The Company is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
1.8¢ 		Change
0.000(0.00%) 		Mkt cap ! $3.072M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 21526 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.5¢ 40003 1
View Market Depth
Last trade - 07.06am 02/10/2024 (20 minute delay) ?
OPL (ASX) Chart

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Canada orders national security review over CGN's 11.26% opposition to Paladin-Fission deal Paladin has disclosed its attempted takeover of Fission Uranium Corp was blocked by a Chinese shareholder late last month.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Argent hits rockchips up to 24g/t gold at Trunkey Creek, NSW Argent Minerals has unveiled rockchips containing gold grading up to 24g/t on-site its NSW-based Trunkey Creek project acreage.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.